GlassScriptPhysician profile
Lisa Weber
NPI 1134126436
$2,123.17
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $256 · 2021: $322 · 2022: $547 · 2023: $430 · 2024: $68.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $275.93 | 2021-2023 | Rayaldee |
| Travere Therapeutics, INC. | $215.99 | 2019-2024 | |
| Horizon Therapeutics Plc | $193.11 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $188.88 | 2019-2023 | Flumist Quadrivalent, Farxiga |
| Mallinckrodt Enterprises LLC | $180.61 | 2019 | |
| Amgen INC. | $174.91 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $121.05 | 2021-2023 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $109.61 | 2019-2023 | Veltassa |
| Akebia Therapeutics INC | $105.42 | 2020 | |
| Amarin Pharma, INC. | $97.58 | 2019 | |
| Glaxosmithkline, LLC. | $94.67 | 2021-2023 | Benlysta |
| Fresenius USA Marketing, INC. | $66.63 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $54.46 | 2021-2023 | Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $38.64 | 2022-2023 | Gattex |
| Calliditas Therapeutics US INC. | $34.45 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $34.36 | 2021-2022 | |
| Abbott Laboratories | $28.41 | 2022-2023 | Freestyle Libre 2 |
| Kyowa Kirin, INC. | $21.81 | 2023 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.68 | 2023 | |
| Shire North American Group INC | $15.47 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.81 | 2019 | |
| Genentech USA, INC. | $13.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.81 | 2023 | |
| Genzyme Corporation | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.